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Nucleic acid vaccines have attracted many attentions since they have presented some superiority over
traditional vaccines. However, they could only induce moderate immunogenicity. The route and formulation of
nucleic acid vaccines have strong effects on the immune response and efficiency. Numerous biomaterials are
used as a tool to enhance the immunogenicity of antigens. They deliver the antigens into the cells through
particle- and non-particle-mediated pathway. However, challenges remain due to lack of comprehensive
understanding of the actions of these biomaterials as a carrier/adjuvant. Herein, this review focuses on the
evolution of biomaterials used for nucleic acid vaccines, discusses the advantages and disadvantages for gene
delivery and immunostimulation of variety of structures of the biomaterials, in order to provide new thought on
rational design of carrier/adjuvant and better understanding of mechanism of action in both immunostimulatory
and delivery methods.
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Since Edward Jenner developed the first cowpox vaccine
as a prophylactic treatment for smallpox in 1796 [1,2],
vaccines have gained remarkable achievements from
then on. Nowadays, vaccines are defined as biological
agents, which are prepared by disease-causing bacteria,
viruses and so on, to stimulate the host’s immune system
for protection from a disease and for treatment. Conven-
tional vaccines, including inactivated, live attenuated vi-
ruses, have made great progress, and some of them have
been used in clinical use [3-6]. However, these vaccines
could also pose potential risks, which highlighted the
need for novel vaccine strategies.
For past two decades, nucleic acid vaccines, including
DNA and RNA, had exhibited a great promise in im-
munotherapy for infectious diseases [7,8], cancers [9,10],
autoimmune diseases [11] and allergy [12]. Nucleic acid
vaccines, namely genetic vaccines, is to deliver genetic
materials encoding the antigens of interest into host cells
and directly express antigen protein in suit, finally* Correspondence: liangxj@nanoctr.cn; xzhang@home.ipe.ac.cn
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from following challenge and disease therapy. Early ad-
ministration of DNA vaccines in mice were through
gene gun technology and naked DNA injection [13,14].
Comparing with conventional vaccines, the nucleic acid
vaccines have represented superiorities, such as good
safety, specific to induce the immune response for the
antigen of interest, induction of both B- and T-cell re-
sponses, relatively low cost of production, and ease of
manufacturing [9,10,15]. Numerous clinical trials of
DNA vaccines have been made, and they have shown
promise in animal models. Like the West Nile Virus
DNA vaccine, safe and well tolerated, has been used to
protect wild Californian condors and licensed for use in
horses [16,17]. However, they have initiated poorly im-
munogenic effects in clinic trials and have not yet used
in human as commercial products [18]. The inherent
barriers of the body limits DNA entering into cells to a
great extent, which results in few antigens produced
after using large scale of DNA, and finally exhibits low
efficiency of immune response. Moreover, the poor sta-
bility and in vivo distribution of the naked form and the
lack of clinical feasible delivery methods hinder the effi-
ciency for nucleic acid vaccines.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vaccine, some strategies were developed to prompt the
permanence and efficiency of the immune responses,
including physical methods (such as electroporation,
sonoporation and magnetofection) [13,19,20]. Among
them, a nucleic acid delivery system is a very promising
strategy for safe and effective immune protection and
therapy, since delivery vectors could improve nucleic
acid stability and immunogenicity, and also targeted de-
livery to certain sites of interest. Ideally, a nucleic acid
vector of vaccines should provide protection from host
enzymes and transport them to the cells of interest–-
antigen presenting cells (APC), such as dendritic cells
(DCs) and macrophage (MP), after endocytosis, they
would help the genetic materials escape from the endo-
somal compartment to where the transfection machin-
ery is located. Following expression of antigens, the
APC processed the antigens with the external stimuli
and migrate to the lymph nodes via the lymphatic cir-
culation, where they presented the antigenic peptides
on major histocompatibility complex (MHC) to CD4+ T
and CD8+ T cells via T cell receptor (TCR), and the acti-
vated CD4+ T cells stimulated the differentiation of B
cells, inducing both humoral and cellular immune re-
sponses (Scheme 1). Various biomaterials were devel-
oped as the delivery vectors for nucleic acid to provide a
controlled releasing and long-lasting protection [21],
and also some of them could elicit enhanced immune
responses as adjuvant [22,23].Scheme 1 Induction of cellular and humoral immunity by DNA vaccin
and release of nucleic acid, (4) entry into nucleus, (5) expression of antigen
of CD4+ (help T-cells, TH) and CD8
+ T cells (cytotoxic T-cells, CTL), (8) stimuFor administration of these nucleic acid vaccines to
the target cells, there are many extra- and intracellular
barriers that must be conquered to promote expression
of antigens, including effective transportation, preven-
tion from degradation, association with APCs, endoso-
mal escape, release of nucleic acids to express antigen
efficiently. Gene delivery should occur in proper routes
with sufficient expression to initiate efficient innate and
adaptive immune responses and generate strong immun-
ity. Considering with these, recent studies for biomate-
rial development applying for nucleic acid vaccines are
reviewed in this work for better understanding the role
of biomaterials as carriers or adjuvant, and discuss the
barriers to antigen expression and immune responses
generation in gene delivery systems, which will provide
new thoughts toward development of rational design of
biomaterials for nucleic acid vaccines. In this review, the
most studied delivery biomaterials for DNA vaccines will
be represented in detail, from the inorganic biomaterials,
polymer, and peptide to lipid-based formulation. The re-
cent reported self-amplifying RNA formulation is also
included since it uses the lipid-based formulation for
gene delivery, which is very helpful for development of
delivery vectors for nucleic acid vaccines.
Review
DNA vaccines
DNA has distinctive features as vaccine, such as it needs
to express the antigenic protein after entering the nuclei,e. (1) transportation to APC, (2) endocytosis, (3) endosomal escape
, (6) antigen processing and presentation through MHC, (7) activation
lation of the differentiation of B cells.
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the DNA vaccines. In order to efficiently deliver DNA
antigen into cell nuclei and enhance the immunogenicity
of DNA vaccines, several strategies on biomaterials have
been investigated.Particle-mediated DNA vaccine
Inorganic biomaterial-based formulation
Many inorganic biomaterials have been exploited as car-
riers/adjuvants for vaccines. Aluminium salts are the
most broadly used immune adjuvants for vaccines by
adsorbing the antigen onto their surfaces [24]. They have
been approved for use in humans. The formulation of
aluminium adjuvants with DNA vaccines could enhance
the antibody responses up to 10–100 folds in small model
of animals [25,26]. However, the aluminium salts exhibited
strong adjuvant effects only when the adjuvant did not
bind to the plasmid DNA. Moreover, they exhibited po-
tential adverse local reactions, easy degradation during
freeze-drying, and demand multiple administrations to
gain long-lasting protection [27,28]. Most importantly, the
adsorption of DNA antigen on the alum surface could not
effectively protect the genetic materials from digestion by
nucleases during the delivery process.
Gold nanoparticles have attracted great attention since
they present promising potential in gene delivery and
immunoassay [29-31]. To facilitate their usage in DNA
vaccine delivery, surface modifications of gold nanoparti-
cles with cationic materials have been applied. For ex-
ample, Chen and Wu et al. reported that gold nanorods
(Au NRs) with proper surface coatings (poly(diallydi-
methylammonium chloride) (PDDAC)) not only acted as
an effective carrier to enhance the cellular uptake of the
DNA, but also facilitated DC maturation directly to ini-
tiate and amplify the immune responses (Scheme 2)
[32]. The positive surface charges of the coatings ren-
dered the DNA escaping from the endosome/lysosome
and transporting into the nucleus to be processed. How-
ever, the type of immune response for the PDDAC-Au
DNA vaccine was Th2-biased and the detailed mecha-
nisms of gold nanorods as adjuvant still needed further in-
vestigation. With altered surface modification, the in vivo
biodistribution and toxicity profile might also require deepScheme 2 The surface coatings process of gold nanoparticles (Au NRs) aexamination [31]. As for inorganic biomaterial nanoparti-
cles, the antigens basically loaded on the peripheral of par-
ticles, which might significant affect the stability and
controllable releasing of the antigens. Moreover, these
nanoparticles are mostly non-biodegradable. The long-
term safety evaluation should also be under consideration
for these biomaterials.Polymer-based formulation
Synthesized polymers
Various synthesized polymers were developed for usage
in delivery of nucleic acid to target cells (Figure 1), in-
cluding polyethyleneimine (PEI) [33,34], poly(L-lysine)
(PLL) [35,36], poly(β-amino ester) [37-39] and so on
[40-42], since they were very feasible for multifunctional
modification. The cationic properties of these polymers
helped them condense with the negatively charged DNA
into complexes particles by electrostatic interactions to
protect the DNA from degradation, and facilitate cellular
uptake by the antigen presenting cells.
PEI, as a very efficient gene delivery vector, has attracted
much more attention since it has high cationic charge po-
tential and facilitates endosomal escape through the hy-
pothesized “proton sponge” mechanism [43,44]. The
costimulatory effect of PEI as adjuvants could enhance the
class I-mediated tumor-specific cytotoxic T lymphocytes
(CTLs) and class II-mediated Th1/Th2 activation when
administrated as PEI-mediated DNA cancer vaccines,
which resulted in suppressed tumor growth and prolonged
survival rate. Branched PEI, especially branched PEI25k, is
widely used as its excellent performance for gene delivery.
However, the severe cytotoxicity inhibits its further appli-
cation. Hence, balance between efficiency and toxicity
should be well considered during construction of delivery
system. Some strategies were exploited to prompt their
applications as adjuvants, such as adopting low-molecular
weight PEI or combination with other biomaterials, which
expressed excellent biocompatibility and biodegradability
[45,46]. A mannosylated PEI/DNA complex was con-
structed with low-molecular weight PEI and used to in-
duce upregulation of surface markers for DC maturation,
which expressed large scale of mannose receptor on the
surface [47,48]. This modified PEI exhibited similars vaccine adjuvants. Reproduced and modified with permission from [32].
Figure 1 The structures of polymers used as DNA delivery carriers.
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had less cytotoxicity and better transfection. These studies
demonstrated that rational modification of the structures
of PEI was very important to regulate the balance between
transfection efficiency and toxicity of the polymers.
Poly(L-lysine) (PLL), as a synthesized polypeptide bio-
material, could be protonated at the primary amino
groups of lysine to interact with DNA. However, it was
limited for use as gene carriers since it had high cationic
toxicity and sufficient escape from endosomes [49].
Herein, though PLL was biodegradable, additional agents
needed to help DNA release from endosomes. Poly(β-
amino ester) (PBAE) could be facile synthesized by amine
and diacrylates to form large scales of combinatorial bio-
materials. This made they had variable structures and tun-
able properties. A combinatorial library of over 2000
PBAE was studied and end-modified PBAE generated sig-
nificant enhancement in gene tranfection in vitro and
in vivo [50]. This approach provided comparable gene de-
livery in vitro in comparison with adenovirus.
Synthesized biomaterials could effectively load the nu-
cleic acid in abundance since they always contained a
large amount of positively charged ions. However, these
cations brought them high toxicity. Considering with the
high and efficient cellular uptake and gene transfection,
strategies to minimize toxicity of these synthesized bio-
materials were very crucial for their application as adju-
vant towards clinic use.
Natural polymers
Natural polymers, like chitosan, have been exploited to act
as vaccine carriers and adjuvants due to their natural non-
toxicity and excellent biocompatibility, and they could beused as an alternative through oral or mucosal routes to
delivery nucleic acid vaccine for protection [51,52]. Nano-
chitosan could help enhance the vaccination effects of
Esat-6/3e-FL DNA vaccine containing Esat-6 three T cell
epitopes and fms-like tyrosine kinase 3 ligand genes
against Mycobacterium tuberculosis (M.tb) by prompting
cellular uptake and protective ability of the vaccine [53].
To enhance the delivery efficiency, mannose receptor-
mediated endocytosis was applied in chitosan-DNA vac-
cine (MCS/pGRP) for nasal mucosal delivery by Zong
et al. [52]. Intranasal immunization with this targeting
nanoparticles elicited strong systemic responses and
significantly higher specific anti-GRP antibody levels
comparing with non-targeting one, and the IgG levels
were 3-fold higher at 7th week.
The linear cationic polysaccharide was facilitated the
mucosal administration method due to the natural
mucoadhesive properties. They represented sustained-
release as nanogels and were a promise delivering carrier
for DNA vaccine. It was worth noting that a proper tar-
geting could effectively enhance specific delivery to APC
and lymph node.
Peptide-based formulation
Peptide and their derivatives have sparked intense attrac-
tions for vaccine applications due to their specific variability
in immunotherapy [54-56]. They compose with nucleic
acids by electrostatic interaction or embedding [57,58]. Like
in 2014, Jiang et. al. developed a short peptide-based nano-
fibrous hydrogel (Nap-GFFY-NMe (G-NMe)) as a safe and
effective nanovector for HIV DNA vaccines, which could
active optimized humoral and cellular immune responses
in mice through three different administration regimens
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(Figure 2) [57]. The G-NMe formed a specific nanofiber
with left-handed structures, which facilitated to condense
with DNA with high loading. The peptide-based carriers
constructed a smart superiority structure for embedding
with DNA without using electrostatic interaction, which
might greatly reduce the toxicity to the host cells.
Moreover, adjuvant was combined for potent and con-
tinuous immunity. Stephen J. Kent and Frank Caruso’s
group designed redox-responsive polypeptide particles
(poly(L-glutamic acid), PGA) with controlled loading cap-
acity by covalently conjugating an oligonucleotide adju-
vant (CpG) with a disulfide bond [56]. The particles
elicited different levels of activation of primary human
blood pDCs population through simply tuning of the load-
ing capacity governed by controlling the cross-linking
density. The mechanically tunable and self-adjuvanting
particles provided a relatively stable and high antigen load-
ing system for improved vaccine immunogenicity.
Lipid-based formulation
Cationic lipids are widely used and recognized as one of
the most promising delivery vectors for nucleic acids as
they could condense nucleic acids to form lipid/nucleic
acids complexes, which protects them from being digested
by nucleases. For gene delivery, nucleic acids are usually
encapsulated into cationic lipid-based liposomes. They
can easily merge with the cell membrane since they areFigure 2 The structure of G-NMe (A) and the process of nanofiber for
of DNA vaccines in mice model (B). Reproduced and modified with permboth made of a phospholipid bilayer. Liposomes could be
modified to suit any antigen by changing their physical
properties, like sizes, surface charge, lipid compositions,
targeting, etc. [59-61], and they could mimic the patho-
gens and exert potent long-lasting immune responses
[62]. Moreover, cationic liposomes could prompt dendritic
cell maturation and induce a series of cytokines and che-
mokines, and some of them have been entered into clin-
ical trials [63,64].
The rational design of liposomes for DNA vaccines
should consider the influence factors for antigen uptake
and trafficking to draining lymph nodes. The lipid compos-
ition, size and surface charge of liposomes, and membrane
fluidity are the structural factors that affect immune re-
sponses. Though there have been made huge efforts to ex-
plore lipid-based formulation, only a few of them have been
approved for clinical use [63]. The clinical applications of li-
posomes remain limited due to in vivo instability, difficulty
in generating reproducible formulation and large-scale of
production, and relatively higher cost. Also, some import-
ant questions need to be addressed, such as the mechanism
of cationic lipids as adjuvants and the real interaction be-
tween lipids and antigens in vivo. These all require deep in-
vestigation in the interconnection of lipid and vaccines.
Non-particle-mediated DNA vaccines
Except particle-mediated DNA delivery, some strategies
were exploited for safe and improved performance. Formed after enzymatic conversion to enhance immune responses
ission from [57].
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layer tattooing approach into the immune-cell-rich epider-
mis, which used coated microneedles as a media for rapid
implantation of multilayer vaccine-loaded polymer firm for
controlled release of DNA and adjuvants (Figure 3) [65].
This strategy induced significant cellular and humoral im-
munity against a HIV antigen, comparable to electropor-
ation. The layer-by-layer structures provided long-term
depot for immune response, which should make the single
dose administration and long-lasting protection possible.
However, this strategy might be difficult for scale up and
widespread use for vaccines as the complicated preparation
technology.
RNA vaccines
Comparing with DNA vaccine, the investigation of RNA
vaccine was relatively less, which might due to the prop-
erties of RNA, such as difficult preparation and less sta-
bility. However, the RNA still attracted many attentionsFigure 3 The illustration of multilayer tattooing strategy with vaccine
process (B). Reproduced and modified with permission from [65].as a promising alternative in prophylactic and thera-
peutic vaccines. They exhibited several advantages over
the DNA vaccines. For example, they could avoid the
nuclear membranous barriers since they exerted their
functions in the cytoplasm. The most studied RNA vac-
cines were with naked RNA, electroporation and lipid-
based formulations [66].
Due to the instability of RNA, the direct injection of
RNA might be not suitable for in vivo transportation
since the rapid enzymic degradation and cellular bar-
riers. An ideal delivery carrier was required for protec-
tion of RNA and targeting for cytoplasm. Recently, a
novel self-amplifying RNA vaccine was developed using
lipid nanoparticles by Andrew J. Geall et al. [23,67]. The
self-amplifying RNA contained the genes encoding anti-
gens of interest and RNA replicon replication and tran-
scription, but lacked the genes encoding structural
proteins (Figure 4). They exhibited comparable potency
with a single-cycle alphavirus vector (1 × 106 IU) at a-loaded microneedle coatings (A) and the controlled release
Figure 4 The illustration of self-amplifying RNA (A) and the construction of the lipid nanoparticles (LNP) encapsulating self-amplifying
RNA (B). Reproduced and modified with permission from [67].
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electroporation at higher doses in vivo. The lipid nanopar-
ticles separated the RNA from contact with the degrada-
tive enzyme by encapsulating the genetic materials. Also,
the liposomes had the similar membranous structures
with the cells, which could fuse with cell membrane for ef-
ficient cellular uptake. Same as the DNA vaccines, the
physicochemical properties of the liposomes were also the
important factors that affect immune responses.
Comparing with DNA vaccine, these RNA vaccines
could bypass the rate-limiting barrier for pDNA delivery
by self-amplifying and expressing in cytoplasm. However,
the in vivo stability and storage strategies of RNA vac-
cines will require further studies to improve the current
status of vaccine development.
Conclusions
Gene-based vaccines have become a favored strategy for
inducing immunity. However, the lower immunogenicity
of nucleic acid vaccines has hindered their progress in
humans. Long-lasting stability and controlled release of
the nucleic acid antigens are crucial for the development
of much more efficient vaccines. From the review of the
development of biomaterials, some important issues
should consider to design the delivering vectors for vac-
cines. Firstly, considering the stability of nucleic acid an-
tigens in vivo, ideal nucleic acid carriers should provide
protection during the delivery process and specific target
to immune tissues. This will greatly enhance the accu-
mulation of nucleic acid antigens in targeting cells, espe-
cially the antigen presenting cells in draining lymph
nodes, which are very crucial for inducing strong immuneresponse. Secondly, the delivery vectors could act as costi-
mulators for vaccines. Like discussion in this review, nu-
merous biomaterial vectors exhibit potential immune
responses due to their tunable mechanical properties and
adjusted multifunction for combining with other costimu-
lators, such as CpG and cytokines. This multifunctional
delivery vector will improve the immunogenicity of nu-
cleic acid vaccines. Thirdly, the delivery vectors should
provide sustained release of nucleic acid antigens, which
will establish the immunological memory for prolonged
surveillance against pathogens or cancer cells.
Herein, diversified and multifunctional biomaterials pro-
vide us numerous strategies for improving the nucleic acid
vaccine performance. However, challenges remain due to
a lack of deep and comprehensive understanding the
in vivo behavior of delivery vectors and immunostimula-
tive mechanism. Therefore, intensive and comprehensive
understanding of the mechanism of biomaterial vector on
both delivery routes and immunostimulatory are very cru-
cial for rational design of delivery vectors for vaccines, and
will accelerate the development of nucleic acid vaccine for
clinical application.
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